Study purpose, risk factors, registries, and funding, 31 SEER biospecimen studies, 2005 to 2013
| Attribute | N | References |
|---|---|---|
| Study purpose | ||
| Etiology | 19 | (10–15, 17, 19, 20, 24, 26–29, 31, 33, 34, 37, 38) |
| Prognosis | 8 | (8, 11, 14, 21–23, 35, 36) |
| Detection, development, and progression | 6 | (16, 18, 24, 33, 37, 38) |
| Risk factors | ||
| HPV | 6 | (14, 15, 17, 20, 31, 34) |
| Tobacco | 3 | (10, 29, 31) |
| Viral hepatitis | 2 | (19, 33) |
| Agricultural chemical exposure | 2 | (12, 13) |
| Other (one each)a | 8 | (10, 24, 26, 27, 28, 33, 37, 38) |
| Registries | ||
| Hawaii | 20 | (8, 9, 14, 15, 17, 22, 24–27, 32–37) |
| Iowa | 19 | (8, 10–17, 20, 21, 23, 25, 26, 29, 30, 34–36) |
| Los Angeles | 15 | (8, 11, 13, 14, 17, 20, 21, 25, 26, 34–36, 38) |
| Detroit, Kentucky, Seattle, Louisiana | 5 | (11, 13, 17, 20, 31) |
| SEER/NPCR collaboration | 3 | (17, 20, 34) |
| Funding | ||
| SEER contract | 30 | (8–30, 32–38) |
| NCI intramural program | 10 | (9, 10, 12–14, 19, 25, 26, 28, 36) |
| CDC NPCR | 3 | (17, 20, 34) |
| Otherb | 3 | (15, 16, 28–31) |
↵aRadon (10), soy intake (24), Epstein-Barr virus infection (26), parity (27), HIV infection (28), alcohol use (33), mammographic tissue density (37), and menopausal hormone therapy (38).
↵bInternational Public and Private Consortium (15), NCI Office of HIV & AIDS Associated Malignancies (28), RO1 grant from NCI (16, 29, 30), and NCI Rapid Response Surveillance Studies (31).